Q32 Bio Announces Closing of Merger with Homology & Placement of $42M
Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
WALTHAM, Mass., Oct. 24, 2023 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio's chemistry, manufacturing and control (CMC)-related activities.
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
WALTHAM, Mass., & DUBLIN--(BUSINESS WIRE)--Oct. 27, 2022-- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 in persistent, moderate-to-severe atopic dermatitis (AD). Q32 Bio and Horizon are developing ADX-914, a fully human anti-IL-7R? antibody that re-regulates adaptive immune function, in collaboration.
WALTHAM, Mass., Sept. 20, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson.
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: ...
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company...
WALTHAM, Mass., May 26, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been initiated in the healthy volunteer portion of its Phase 1, single ascending dose and multiple ascending dose (SAD/MAD) clinical study evaluating ADX-097, a first-in-class fusion protein, for the treatment of complement disorders. ADX-097 is a tissue-targeted inhibitor of complement activation that minimizes systemic complement blockade and is being investigated for the treatment of patients with skin and renal diseases associated with increased complement activation.